Cart
sales@molnova.com
DB213
CAS No. 209163-39-3
DB213 ( RG-501 )
Catalog No. M13275 CAS No. 209163-39-3
DB213 (RG-501) is a small molecule stimulator of HIV-1 frameshifting and inhibitor of viral replication.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDB213
-
NoteResearch use only, not for human use.
-
Brief DescriptionDB213 (RG-501) is a small molecule stimulator of HIV-1 frameshifting and inhibitor of viral replication.
-
DescriptionDB213 (RG-501) is a small molecule stimulator of HIV-1 frameshifting and inhibitor of viral replication; causes an imbalance in the ratio of Gag to Gag-Pol, and inhibits viral particle assembly.
-
SynonymsRG-501
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number209163-39-3
-
Formula Weight478.33
-
Molecular FormulaC18H36Cl4N6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN1,N4-bis(3-(dimethylamino)propyl)terephthalimidamide tetrahydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Marcheschi RJ, et al. ACS Chem Biol. 2011 Aug 19;6(8):857-64.
2. Hung M, et al. J Virol. 1998 Jun;72(6):4819-24.
3. Wang Q, et al. J Pharm Biomed Anal. 2016 Jun 5;125:41-7.
2. Hung M, et al. J Virol. 1998 Jun;72(6):4819-24.
3. Wang Q, et al. J Pharm Biomed Anal. 2016 Jun 5;125:41-7.
molnova catalog
related products
-
Peptide T TFA
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
-
GS-9822
GS-9822 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 3 nM.
-
BNM-III-170 trifluor...
BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.
